A PHASE 1A/1B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SINGLE AND MULTIPLE ASCENDING DOSES OF EDP-514 IN HEALTHY SUBJECTS (PART 1), AND ANTIVIRAL ACTIVITY IN NUCLEOS(T)IDE REVERSE TRANSCRIPTASE INHIBITOR (NUC)-SUPPRESSED PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION (PART 2)

Registry ID
EDP 514-001
Source registry
HEALTH_CANADA
Status
Closed
Phase
PHASE1
Study type
INTERVENTIONAL
Sponsor
ENANTA PHARMACEUTICALS INC
Start date
2020-11-01
Completion date
2021-07-14
Last update
2020-01-10

Conditions

Related clinical trials

View on source registry